Aurobindo Pharma Ltd is set to acquire Lannett Company LLC for $250 million after receiving approval from the U.S. Federal Trade Commission (FTC), a move aimed at strengthening its presence in the US generic drugs market.
The transaction, through wholly owned subsidiary Aurobindo Pharma USA, is expected to close before the end of June 2026.
Shares of Aurobindo Pharma were trading at ₹1,512, up 1.32% from the previous close. The company has a market capitalisation of ₹87,817 crore and has delivered a return of 60.5% over the past five years.
What the Deal Brings
The acquisition will expand Aurobindo Pharma’s product portfolio in the US and add Lannett’s manufacturing facility in Seymour, Indiana.
The plant has the capacity to produce nearly 4 billion doses annually.
Management expects the deal to be immediately earnings accretive and to generate benefits from operational synergies and cost efficiencies over time.
How the Acquisition Could Support Growth
The Lannett deal is expected to provide several advantages for Aurobindo Pharma’s US business.
Faster Revenue Growth in the US
The acquisition could help Aurobindo increase its US revenue to nearly $2 billion in FY27, compared with about $1.6 billion in FY26.
Higher scale in its largest market may support future growth.
Addition of Complex Generic Products
Lannett’s portfolio will add more complex generics to Aurobindo’s offerings.
These products generally have:
- Higher entry barriers.
- Better pricing power.
- Greater margin potential.
- Exposure to specialised segments.
Increased Manufacturing Capacity
The deal will also expand Aurobindo’s manufacturing footprint in the US.
Additional capacity could:
- Improve utilisation levels.
- Enhance operating leverage.
- Spread fixed costs over higher production volumes.
- Support margins over time.
Support for Long-Term Earnings
The acquisition comes with potential upside from products under development, including the planned launch of a generic version of Advair in the US.
Expected benefits include:
- Cost synergies.
- Operational efficiencies.
- Pipeline expansion.
- Improvement in long-term profitability.
HSBC Maintains Buy Rating
HSBC has maintained a Buy rating on Aurobindo Pharma with a target price of ₹1,580.
The brokerage cited:
- Benefits from the Lannett acquisition.
- Potential gains from the planned Advair launch.
- Better growth visibility in the US market.
Management View
Swami S. Iyer, Chief Executive Officer of Aurobindo Pharma USA, described the acquisition as a strategic and financial move that would support revenue growth and enhance manufacturing capabilities in the US.
He said the transaction would strengthen Aurobindo’s presence in complex non-opioid controlled substances and create long-term value through synergies, pipeline expansion and the combined capabilities of the two companies.
Financial Performance
In Q4 FY26, revenue from operations rose 6% to ₹8,853 crore, compared with ₹8,382 crore in the year-ago period.
EBITDA slipped 1% to ₹1,750 crore from ₹1,760 crore.
Net profit increased 2% to ₹921 crore, against ₹903 crore a year earlier.
Earnings per share also rose 2% to ₹15.86, compared with ₹15.56 in Q4 FY25.
About the Company
Headquartered in Hyderabad, Aurobindo Pharma manufactures generic medicines, branded specialty drugs and active pharmaceutical ingredients.
The company operates in more than 150 countries and is among the largest generic pharmaceutical companies in the US by prescriptions dispensed.
TL;DR:
Aurobindo Pharma has secured FTC approval for its $250 million acquisition of Lannett. The deal is expected to strengthen its US business, add complex generics, increase manufacturing capacity and support long-term earnings growth.
AI summary:
- FTC has approved Aurobindo Pharma’s $250 million acquisition of Lannett.
- The deal is expected to close before the end of June 2026.
- Lannett’s Indiana facility can produce nearly 4 billion doses annually.
- HSBC has retained a Buy rating with a target price of ₹1,580.
- Aurobindo reported 6% revenue growth and 2% growth in net profit in Q4 FY26.
